Ligand price target raised to $388 from $266 at BofA
BofA analyst Jason Zemansky raised the firm's price target on Ligand to $388 from $266 and keeps a Buy rating on the shares. Despite strong share performance, Ligand's growth opportunity remains underappreciated, with the XOMA acquisition expanding its royalty portfolio, diversification, scalability, and earnings potential while strengthening its balance sheet, the analyst tells investors in a research note.
BofA analyst Jason Zemansky raised the firm's price target on Ligand to $388 from $266 and keeps a Buy rating on the shares.
Despite strong share performance, Ligand's growth opportunity remains underappreciated, with the XOMA acquisition expanding its royalty portfolio, diversification, scalability, and earnings potential while strengthening its balance sheet, the analyst tells investors in a research note.